Two Anti-TNFs Effective in Immune Uveitis (CME/CE)

by MedPage Today • 2016/04/08 • 0 Comments

(MedPage Today) -- Overall response rates were 97% and 95% for infliximab and adalimumab

← Global Ophthalmic Diagnostic Equipment Market Report 2015-2025 – Analysis, Technologies & Forecasts – Key Vendors: Ellex, Halma, NIDEK – Research and Markets

Inotek reports $68 million net loss in 2015 →